Constellation Pharmaceuticals Inc (NASDAQ:CNST) – Investment analysts at Jefferies Financial Group decreased their Q2 2019 earnings estimates for shares of Constellation Pharmaceuticals in a research note issued to investors on Monday, May 13th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.77). Jefferies Financial Group also issued estimates for Constellation Pharmaceuticals’ Q3 2019 earnings at ($0.77) EPS, Q4 2019 earnings at ($0.58) EPS, FY2019 earnings at ($2.83) EPS, FY2020 earnings at ($3.10) EPS, FY2021 earnings at ($1.89) EPS, FY2022 earnings at ($4.47) EPS and FY2023 earnings at ($3.32) EPS.
Several other research analysts have also weighed in on CNST. ValuEngine lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Robert W. Baird initiated coverage on Constellation Pharmaceuticals in a research report on Monday, January 28th. They issued an “outperform” rating and a $17.00 target price on the stock. Zacks Investment Research lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. Finally, Oppenheimer upped their target price on Constellation Pharmaceuticals from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Constellation Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $16.82.
Constellation Pharmaceuticals (NASDAQ:CNST) last issued its earnings results on Wednesday, May 8th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.05.
A number of hedge funds have recently modified their holdings of the business. Svennilson Peter bought a new stake in shares of Constellation Pharmaceuticals during the 4th quarter worth about $18,759,000. BlackRock Inc. boosted its stake in shares of Constellation Pharmaceuticals by 582.3% during the 1st quarter. BlackRock Inc. now owns 726,325 shares of the company’s stock worth $9,842,000 after acquiring an additional 619,868 shares in the last quarter. Casdin Capital LLC boosted its stake in shares of Constellation Pharmaceuticals by 18.4% during the 4th quarter. Casdin Capital LLC now owns 1,556,998 shares of the company’s stock worth $6,244,000 after acquiring an additional 242,255 shares in the last quarter. Vanguard Group Inc bought a new stake in shares of Constellation Pharmaceuticals during the 3rd quarter worth about $989,000. Finally, Vanguard Group Inc. bought a new stake in shares of Constellation Pharmaceuticals during the 3rd quarter worth about $989,000. 60.12% of the stock is currently owned by institutional investors.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Further Reading: Do stock splits help investors?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.